EJC Supplements
Volume 5, Issue 2 , Pages 32-42 , July 2007

Empirical antifungal therapy in neutropaenic cancer patients with persistent fever

  • Oscar Marchetti

      Affiliations

    • Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland
    • Corresponding Author InformationCorresponding author: Tel.: +41 21 314 10 10; fax: +41 21 314 10 18.
    • ,
  • Catherine Cordonnier

      Affiliations

    • Hematology Service, Hôpital Henri Mondor, Créteil, France
    • ,
  • Thierry Calandra

      Affiliations

    • Infectious Diseases Service, Department of Medicine, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland

Received 14 May 2007 ,Revised 5 June 2007 ,Accepted 11 June 2007.

References 

  1. DeGregorio MW, Lee W, Linker CA, et al. Fungal infections in patients with acute leukemia. Am J Med. 1982;73:543–548
  2. Wald A, Leisenring W, van Burik JA, et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis. 1997;175:1459–1466
  3. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730–751
  4. Bodey GP, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autospy survey. Eur J Clin Microbiol Infect Dis. 1992;11:99–109
  5. Pizzo PA, Robichaud KJ, Gill FA, et al. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72:101–111
  6. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med 1989;86:668–72.
  7. Leenders AC, Daenen S, Jansen RL, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol. 1998;103:205–212
  8. Fleming RV, Kantarjian HM, Husni R, et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma. 2001;40:511–520
  9. van’t Wout JW, Novakova I, Verhagen CA, et al. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect. 1991;22:45–52
  10. Fainstein V, Bodey GP, Elting L, et al. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrob Agents Chemother. 1987;31:11–15
  11. Silling G, Fegeler W, Roos N, et al. Early empiric antifungal therapy of infections in neutropenic patients comparing fluconazole with amphotericin B/flucytosine. Mycoses. 1999;42(Suppl 2):101–104
  12. Malik IA, Moid I, Aziz Z, et al. A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med. 1998;105:478–483
  13. Viscoli C, Castagnola E, Van Lint MT, et al. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. Eur J Cancer A. 1996;32A:814–820
  14. Ellis ME, Halim MA, Spence D, et al. Systemic amphotericin B versus fluconazole in the management of antibiotic resistant neutropenic fever – preliminary observations from a pilot, exploratory study. J Infect. 1995;30:141–146
  15. Walsh TJ, Rubin M, Hathorn J, et al. Amphotericin B vs high-dose ketoconazole for empirical antifungal therapy among febrile, granulocytopenic cancer patients. A prospective, randomized study. Arch Intern Med. 1991;151:765–770
  16. Marie J, Lapierre V, Pico J, et al. Etude multicentrique randomisée fluconazole IV versus amphotéricine B IV chez le patient neutropénique et fébrile. Cah Oncol. 1993;2:171–173
  17. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ. 2001;322:579–582
  18. Subira M, Martino R, Gomez L, et al. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies – a randomized, controlled trial. Eur J Haematol. 2004;72:342–347
  19. Nucci M, Loureiro M, Silveira F, et al. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with cancer patients. Antimicrob Agents Chemother. 1999;43:1445–1448
  20. Caillot D, Reny G, Solary E, et al. A controlled trial of the tolerance of amphotericin B infused in dextrose or in Intralipid in patients with haematological malignancies. J Antimicrob Chemother. 1994;33:603–613
  21. Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997;98:711–718
  22. White MH, Bowden RA, Sandler ES, et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis. 1998;27:296–302
  23. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340:764–771
  24. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis. 2000;31:1155–1163
  25. Winston DJ, Hathorn JW, Schuster MG, et al. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med. 2000;108:282–289
  26. Boogaerts M, Winston DJ, Bow E, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. Ann Intern Med. 2001;135:412–422
  27. Ehninger G, Schuler UE, Bammer S et al. Intravenous followed by oral itraconazole versus intravenous amphotericin B as empirical antifungal therapy for febrile neutropenic haematological cancer patients. Blood 2002; 100 [Abs. 3631].
  28. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346:225–234
  29. Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351:1391–1402
  30. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41:1242–1250

☆ The ECIL-1 is a common initiative of the following groups or organisations: Infectious Diseases Working Party of the European Blood and Marrow Transplantation Group (EBMT-IDWP), Infectious Diseases Group of the European Organization for Research and Treatment of Cancer (EORTC-IDG), European Leukemia Net (ELN) (EU Grant No.: LSHC-CT-2004), and International Immunocompromised Host Society (ICHS).

PII: S1359-6349(07)00007-9

doi: 10.1016/j.ejcsup.2007.06.005

EJC Supplements
Volume 5, Issue 2 , Pages 32-42 , July 2007

Article Tools

* Image Usage & Resolution